Kaiming Li 个人学术档案 - 学术资源搜索

2019202020212022202320241 12 26 30 30 27

开放获取的出版物数量

3 篇文章

1 篇文章

可查看的文章

无法查看的文章

根据资助方的强制性开放获取政策

Matthew E RitchieThe Walter and Eliza Hall Institute of Medical Research在 wehi.edu.au 的电子邮件经过验证
Gavin M WrightSt Vincent's Hospital在 svhm.org.au 的电子邮件经过验证
James E VinceThe Walter and Eliza Hall Institute of Medical Research在 wehi.edu.au 的电子邮件经过验证
Xueyi DongWalter and Eliza Hall Institute of Medical Research在 wehi.edu.au 的电子邮件经过验证
Sarah BestThe Walter and Eliza Hall Institute of Medical Research (Australia)在 wehi.edu.au 的电子邮件经过验证
Xianchi Dong在 crystal.harvard.edu 的电子邮件经过验证
Wenjie guoNanjing University在 nju.edu.cn 的电子邮件经过验证

Kaiming Li

在 wehi.edu.au 的电子邮件经过验证 - 首页


标题按引用次数排序按年份排序按标题排序	引用次数引用次数	年份
Distinct initiating events underpin the immune and metabolic heterogeneity of KRAS-mutant lung adenocarcinoma SA Best, S Ding, A Kersbergen, X Dong, JY Song, Y Xie, B Reljic, K Li, ... Nature communications 10 (1), 4190, 2019	81	2019
Too much death can kill you: inhibiting intrinsic apoptosis to treat disease K Li, MF van Delft, G Dewson The EMBO Journal 40 (14), e107341, 2021	38	2021
Apo-form selective inhibition of IDO for tumor immunotherapy W Liu, Y Zou, K Li, H Zhong, L Yu, S Ge, Y Lai, X Dong, Q Xu, W Guo The Journal of Immunology 209 (1), 180-191, 2022	8	2022
Correction: Apo-Form Selective Inhibition of IDO for Tumor Immunotherapy W Liu, Y Zou, K Li, H Zhong, L Yu, S Ge, Y Lai, X Dong, Q Xu, W Guo The Journal of Immunology 211 (1), 163-163, 2023		2023
Discovery of a potent apo-IDO1 inhibitor for cancer immunotherapy W Liu, Y Zou, K Li, S Ge, H Zhong, Y Wang, Y Hu, Y Lai, X Dong, W Guo, ... Authorea Preprints, 2020		2020

系统目前无法执行此操作，请稍后再试。

文章 1–5

每年引用数